BGU researchers identify a gene for nearsightedness
A Ben-Gurion University of the Negev research group led by Prof. Ohad Birk has identified a gene that leads to nearsightedness. In an article appearing online in the American Journal of Human genetics this Thursday, Birk and his team reveal that a mutation in LEPREL1 has been shown to cause myopia (nearsightedness) in a Bedouin tribe in southern Israel.
In a manuscript in the American Journal of Human Genetics, a research group led by Prof. Birk of the Morris Kahn Laboratory of Human Genetics at the National Institute for Biotechnology in the Negev (NIBN) at Ben-Gurion University of the Negev and the Dayan clinical genetics wing at Soroka University Medical Center describe the first gene whose defect specifically causes myopia. The gene, LEPREL1, encodes an enzyme that is essential for the final modification of collagen in the eye. In the absence of the active form of this enzyme, aberrant collagen is formed, causing the human eyeball to be longer than normal. As a consequence, light beams entering the eyeball focus in front of the retina rather than on the retina itself and myopia emerges.
The defective gene was identified in a thorough study of severe early-onset myopia that is common in a specific Bedouin tribe in southern Israel. As part of the research and in collaboration with a Finnish group, studies in a model system using insect cells demonstrated that the mutation is detrimental to the enzymatic activity of the enzyme.
"We are finally beginning to understand at a molecular level why nearsightedness occurs," Prof. Birk says.
Future studies will elucidate whether LEPREL1 or its related genes play a significant role in the causation of myopia in the population at large as well. The study was largely carried out by Shikma Levin and Dr. Libe Gradstein of Birk's research group, and was supported by the Kahn Family Foundation.
Prof. Birk's group has thus far elucidated the molecular mechanisms leading to more than 15 human diseases, and the research findings are effectively implemented in massive screening tests and prevention programs.
Most read news
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Nottinghamshire_Deaf_Society

Therapeutic drug renders cancer cell weapon harmless - Already approved drug could pave way to new pharmaceuticals

New tests identify very early changes in Alzheimer's disease before symptoms appear
List_of_Panaeolus_species

Targeted drug delivery with these nanoparticles can make medicines more effective
